Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.65 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382807 | 0.92 | SLC5A1 (0.66) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL30383521 | 0.92 | SLC5A1 (0.66) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL3673937 | 0.92 | SLC5A1 (0.66) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL25223332 | 0.92 | SLC5A1 (0.66) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL31233231 | 0.92 | SLC5A1 (0.66) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL13657210 | 0.90 | SLC5A1 (0.80) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL4883627 | 0.90 | SLC5A1 (0.80) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL30384339 | 0.90 | SLC5A1 (0.80) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL30384783 | 0.90 | SLC5A1 (0.80) | SLC5A1SLC5A2PDE4APDE4BPDE4C | |
| SCHEMBL1727986 | 0.90 | SLC5A1 (0.72) | SLC5A1SLC5A2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | SLC5A1 3752/4885SLC5A2 4208/4885PDE4A 3506/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | SLC5A1 4485/4885SLC5A2 4756/4885PDE4A 3576/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | SLC5A1 4485/4885SLC5A2 4756/4885PDE4A 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.